Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 47 for:    "Central Nervous System Lymphoma" | "Vitamin B Complex"

Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma (BLOCAGE-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02313389
Recruitment Status : Recruiting
First Posted : December 10, 2014
Last Update Posted : August 20, 2019
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

Hypothesis

Our hypothesis is that maintenance chemotherapy will prolong complete remission obtained after a standard induction chemotherapy with an acceptable toxicity in the elderly.

Rationale

  • Treatment of the elderly is challenging, indeed age over 60 is associated both with a poor prognosis and a high risk of treatment induced neurotoxicity with devastating consequences on quality of life. Therefore it has become standard practice to treat elderly in first line with high-dose methotrexate (MTX) based polychemotherapy alone, avoiding whole brain radiotherapy (WBRT) or deferring it for recurrence.
  • There is a clear need to improve disease control after induction chemotherapy. Since consolidation with WBRT or intensive chemotherapy with autologous stem cell rescue are either poorly effective and/or too toxic in the elderly population, maintenance chemotherapy is an interesting alternative approach. Several agents, such as high-dose MTX, temozolomide (TMZ), rituximab, with a reported activity in PCNSL and acceptable safety profile, as single agent or combined, are good candidates for maintenance

Condition or disease Intervention/treatment Phase
Primary Central Nervous System Lymphoma Drug: Rituximab, Methotrexate, Temozolomide Phase 3

  Hide Detailed Description

Detailed Description:

Objectives

  • The primary objective is to evaluate the benefit estimated by the PFS associated with maintenance chemotherapy compared to observation in patients ≥ 60 years having achieved a complete response after a high-dose MTX based induction chemotherapy
  • The secondary objectives are to assess:

    • Overall survival
    • Safety of maintenance chemotherapy
    • Neurocognitive outcome
    • Quality of life of the patients

Inclusion and exclusion criteria

At registration

  • Inclusion criteria

    • Newly diagnosed primary cerebral lymphoma
    • Age >60 years
    • Pathology proven diagnosis
    • Positive cytology of the CSF or vitreous
    • Karnofsky Performance Status >40
    • No evidence of systemic NHL (body CT scan, bone marrow biopsy)
    • Adequate haematological, renal and hepatic function
    • Calculated creatinine clearance > 40 ml/min
  • Non inclusion criteria

    • Positive HIV serology
    • Preexisting immunodeficiency (organ transplant recipient)
    • Prior treatment for PCNSL
    • Isolated primary intra-ocular lymphoma
    • Low grade lymphoma
    • Any other active primary malignancy

At randomization

  • Complete response on MRI after induction chemotherapy according to the IPCG criteria
  • Karnofsky Performance Status >40
  • Adequate haematological, renal and hepatic function

Study Design

  • This study is an open label multicenter randomized phase III trial comparing maintenance chemotherapy versus observation in complete responders to high dose MTX based induction chemotherapy.
  • Patients are registered to participate in the study at time of initial diagnosis and study enrolment before the induction chemotherapy.
  • Induction chemotherapy (R-MPVA protocol) includes 4 to 5 monthly cycles of high dose MTX (3.5g/m2, D1 and D15), procarbazine, vincristine, rituximab followed by one cycle of high dose cytarabine consolidation.
  • Randomization to observation (arm 1) or maintenance (arm 2) will be carried out only for patients in complete response (CR) after induction chemotherapy Arm 1: Observation Arm 2: Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab

Sample size, duration of the study, feasibility

  • 295 patients need to be enrolled to randomize 192 patients
  • Duration of the study: 6 years (accrual period= 4 years; minimal follow-up = 2 years)

    26 participating expert centers from the national LOC network

The trial is supported by the neurooncology ANOCEF and the lymphoma LYSA clinical research groups.

Ancillary study LOCALYSE:

Role of [18F]-FDG brain PET in newly diagnosed primary cerebral lymphoma, in immunocompetent patient older than 60 years

Rationale Patients older than 60 years account for half of cases of PCNSL and have a poorer outcome. No prognostic or predictive factors exist for survival after initial remission. [18F]FDG-PET (Fluoro Deoxy Glucose) plays a key role in grading and therapy monitoring of systemic diffuse large B-cell type.

LOCALYZE is an ancillary PET/MR clinical study from BLOCAGE 01. The aim is to evaluate the usefulness of [18F]FDG-PET to monitor treatment response in PCNSL (Primary Central Nervous System Lymphoma) older than 60 years (n=56), in complement to multiparametric MRI.

Hypothesis We assume that the development of new imaging biomarker extracted from PET imaging and multiparametric MRI, could improve the assessment of treatment response in PCNSL.

Primary aim To evaluate the predictive value of [18F]FDG-PET assessment performed at the end-of-treatment (high-dose methotrexate based polychemotherapy), on progression free survival in newly diagnosed PCNSL with age ≥60 years (n=56).

Primary Outcome Measures:

Progression free survival calculated from the date of completion of the end of chemotherapy PET

Study design

Three [18F]-FDG PET/MR will be performed in the Department of Nuclear Medicine - Pitié-Salpêtrière Hospital:

  • prior to initiation of R-MPVA chemotherapy (Rituximab Methotrexate Procarbazine Vincristine Aracytine ) (PET#1),
  • after two chemotherapy cycles (PET#2),
  • at the end of the first-line chemotherapy regimens (PET#3).

Inclusion criteria (=Blocage-01) Blocage01 eligibility

Exclusion criteria

  • Uncontrolled diabetes with fasting glycaemia > 200 mg/dL
  • Sensitivity to active substance in [18F]-FDG
  • Calculated creatinine clearance < 40 ml/min
  • No contraindication to MRI

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 295 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line
Study Start Date : September 2015
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2022


Arm Intervention/treatment
Experimental: maintenance chemotherapy

Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.

Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months

Drug: Rituximab, Methotrexate, Temozolomide
Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.

No Intervention: observation

Clinical examination and MRI will be performed every 3 months for 2 years and then every 6 months until tumor progression.

Neurocognitive tests will be performed at randomization and annually. Quality of life questionnaires at randomisation and every 3 months




Primary Outcome Measures :
  1. progression free survival [ Time Frame: 6 years ]

Secondary Outcome Measures :
  1. overall survival [ Time Frame: 6 years ]
  2. Toxicity graded according to the NCI-CTCAE [ Time Frame: 6 years ]
    Toxicity graded according to the NCI-CTCAE

  3. Cognitive functions evaluated by a standardized and validated test battery exploring 5 cognitive domains [ Time Frame: 6 years ]
    Cognitive functions evaluated by a standardized and validated test battery exploring 5 cognitive domains

  4. Quality of life [ Time Frame: 6 years ]
    Quality of life assessed by the EORTC QLC-C30 questionnaire and the brain cancer module (BCM20)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria At registration Inclusion criteria

  • newly diagnosed primary cerebral lymphoma
  • Age ≥60 years
  • Pathology proven diagnosis or positive cytology of the CSF or vitreous
  • Karnofsky Performance Status ≥40
  • No evidence of systemic NHL (body CT scan, bone marrow biopsy)
  • Adequate haematological, renal and hepatic function
  • Calculated creatinine clearance > 40 ml/min

At randomization

  • Complete response on MRI after induction chemotherapy according to the IPCG criteria
  • Karnofsky Performance Status ≥40
  • Adequate haematological, renal and hepatic function

Exclusion criteria

  • Positive HIV serology
  • Preexisting immunodeficiency (organ transplant recipient)
  • Prior treatment for PCNSL
  • Isolated primary intra-ocular lymphoma
  • Low grade lymphoma
  • Any other active primary malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02313389


Contacts
Layout table for location contacts
Contact: Khe HOANG-XUAN, MD, PhD +33 - 1.42.16.03.81 khe.hoang-xuan@psl.aphp.fr

Locations
Layout table for location information
France
Groupe Hospitalier Pitie Salpetriere Recruiting
Paris, France, 75013
Contact: Khe HOANG-XUAN, MD, PhD    +33 - 1.42.16.03.81    khe.hoang-xuan@psl.aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Layout table for investigator information
Principal Investigator: Khe HOANG-XUAN, Md, PhD Assistance Publique - Hôpitaux de Paris

Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02313389     History of Changes
Other Study ID Numbers: P130950
2014-002597-37 ( EudraCT Number )
First Posted: December 10, 2014    Key Record Dates
Last Update Posted: August 20, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Folic Acid Antagonists
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Rituximab
Methotrexate
Temozolomide
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Dermatologic Agents
Enzyme Inhibitors
Immunosuppressive Agents
Nucleic Acid Synthesis Inhibitors
Antineoplastic Agents, Alkylating
Alkylating Agents